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Introduction
Vascular-targeted photodynamic therapy (VTP) with 
TOOKAD® Soluble is a focal therapy procedure currently 
assessed in localized prostate cancer treatment [1–3]. VTP 
destroys targeted tissues using a photosensitizer [TOOKAD® 
Soluble (WST11), STEBA Biotech] in association with a low 
power near-infrared laser light in the presence of oxygen. The 
photosensitizer absorbs light and transfers energy to oxygen 
molecules creating reactive oxygen species inducing local 
vascular occlusion resulting in cell destruction [4]. It is intra-
venously infused and circulates systemically while only the 
targeted area of the prostate is illuminated [5]. It induces irre-
versible damage to cell membranes and small arterioles [6] 
and blocks blood and nutriment supply to tumors by exten-
sive effects on tumoral vasculature by taking advantage of 
its sensitivity to stress [7]. Damage to vascular endothelium 
is quickly followed by a cascade of events, including throm-
bosis, blood stasis, and vessel occlusion, leading to tumor 
necrosis [8–10].
TOOKAD® Soluble VTP procedure is indicated in 
patient suffering from localized prostate considered eligible 
for focal treatment. Optimal results are obtained for pros-
tate volume between 25 and 70 cc.
The absolute contra-indications are as follows: a prior 
prostate surgery, an acute urinary retention in the last 
6 months, and history of urethral stricture disease. This 
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procedure was first performed in 2004 by John Trachten-
berg in the Princess Margaret Cancer Center in Toronto on 
a series of patients presenting recurrent prostate cancer fol-
lowing radiation failure. It was then imported in Europe 
by Mark Emberton at the University College Hospital, 
London.
The aim of this article was to report the technical aspects 
of the TOOKAD® Soluble VTP procedure and how it 
has been standardized during the phase II and III trials in 
Europe, North America and Latin America.
Pre‑operative preparation of the patient
An alpha-blocker was advised a week before the pro-
cedure for a period of 1 month in order to ease the 
lower urinary tract symptoms (LUTS) due to prostate 
swelling during the immediate postoperative period 
(2–3 weeks).
A rectal preparation was performed the day before 
surgery.
The treatment guidance by imagery
The treatment guidance by imagery (either by MRI or by 
ultrasound) permitted to define the target volume to treat, 
the safety margin regarding the urethra, posterior, lateral 
capsula and rectal wall. The integrity of these anatomical 
structures had to be strictly respected during the procedure. 
It was performed with a software called TOOGUIDE® 
(Stebabiotech) which optimizes the parameters of treat-
ment: number of optical fibers, accurate position of the 
Fig. 1  TOOGUIDE® treat-
ment guidance. The position 
of the fibers is determined on 
either prostatic MRI/or prostatic 
ultrasound
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fibers into the prostate and the length of the light diffusing 
of each optical fiber (Steba-Biotech) [11] (Fig. 1).
Installation
General anesthesia was mandatory. Peridural or local anes-
thesias were not indicated, and curarization was recom-
mended because of the absolute necessity of a complete 
immobility of the patient during the whole procedure in 
order to keep the safety and the efficacy of the treatment 
in optimal conditions. Indeed, any movement of the patient 
during the procedure should lead to a complete reinstalla-
tion of all transperineal fiber insertion catheters (FIC). The 
Anesthesiologist was informed of this requirement before 
the procedure, and a zero movement rule was mandatory.
The patient was placed in lithotomy position at the edge 
of the operating table with enough hip flexion in order to 
expose the perineum without being hindered by the pubis. 
As in brachytherapy, the legs had to be spread to avoid a 
conflict between the pubic arch and the insertion of the 
FIC.
Fig. 1  continued
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Conventionally, the ultrasound machine was on the left 
of the surgeon, the nurse, her table and the laser, on the 
right (Figs. 2, 3).
The prostate and the adjacent structures were visual-
ized by the biplane trans-rectal ultrasound probe attached 
to a standard brachytherapy stepper (Civco, USA) with an 
attached transperineal prostate template (i.e. Mic Radio 
Nucelar Instruments Inc 0308-02-13 B&K or compatible). 
Biplane vision was mandatory in the choice of the TRUS 
scan machine. Before the insertion of the TRUS probe, 
it was capital to make the rectum perfectly clean with no 
residual feces. A feeding syringe with saline solution can 
be used. This point was capital since the image had to 
remain optimal during the whole procedure especially 
because there is no opportunity to correct it once started 
(Fig. 4).
The probe was covered by a protective endo-cavity bal-
loon previously filled with urethral gel. The urethral gel 
was more appropriate than ultrasound gel because it con-
tains fewer bubbles and facilitates the introduction of the 
probe in the balloon (Fig. 5). Thus, the quality of the pic-
ture improved in order to reach an MRI-like definition. The 










Fig. 3  The operating room organization. The position of the material 
(right or left) depends on the habits of the urologist
Fig. 4  Cleaning the rectum
Fig. 5  The balloon, the saline syringe and the urethral gel
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probe preparation should be performed with the probe on 
the US machine fixed into the stabilizer of the brachystep-
per in order to avoid any damage to the probe and to allow 
the surgeon to perform this step without any external help. 
The balloon was strongly fixed by a rubber band to avoid 
TRUS probe movements inside the balloon. Otherwise, the 
balloon may stay stuck in the rectum allowing the probe to 
move in and out the balloon.
Before introducing the TRUS probe in the rectum, the 
brachystepper had to be set on a neutral position to allow 
movements in all directions. Pointing the stepper toward 
the floor while inflating the balloon removed spontaneously 
the residual bubbles (Fig. 6). Ten to fifteen cc of saline was 
injected into the balloon using a 20-cc luer-lock syringe in 
order to optimize the passage of the ultrasounds through the 
acoustic window without compressing the posterior part of 
the prostate. This detail was important since the compres-
sion of the prostatic tissue and particularly the peripheral 
zone would modify the shape of the targeted volume and 
might modify the blood flow in the prostate and compro-
mise the efficacy of the technique. Furthermore, by com-
pressing the prostate, the distance FIC–FIC or FIC–capsula 
would be artificially reduced during the procedure. Eventu-
ally, inflating the balloon allowed to adjust the position of 
the prostate on the screen.
When the probe was introduced into the rectum, it was 
advised to remove it two or three times in order to empty 
the remaining saline trapped into the rectum after its clean-
ing. Once the TRUS probe was in position, an optimal pic-
ture was sought by adjusting: the frequency to 5–6 MHz, 
the width by focusing the ultrasounds on the prostate, the 
depth to increase the size of the prostate at its maximum on 
the screen, and the resolution of the image. Once an opti-
mal image was obtained, the stepper device was locked, 
and only longitudinal (superior–inferior) movements were 
permitted thereafter.
Using the TOOGUIDE TRUS® software (Steba-Bio-
tech), the US images of the prostate were acquired by 
steps of 5 mm from the basis to the apex by mobilization 
of the stepper. The pictures were saved on the ultrasound 
machine and transferred to the software. The Urologist had 
to delineate the prostate limits and to launch the software 
in order to produce the treatment guidance within 2 min 
(Fig. 1).
The patient’s skin was scrubbed with an antiseptic such 
as povidone iodine or chlorhexidine or equivalent; then, the 
patient was draped with two leg drapes, and then a sterile 
transparent plastic drape covered the brachystepper and the 
probe (eventually two medium-sized drapes delimitating the 
surgical field including the penis and the perineum). These 
two drapes were fixed to the transparent drape to completely 
close the sterile operative area. The keyboard of the ultra-
sound machine was also covered with a transparent sterile 
drape to allow the urologist to independently manage the US 
measurements.
The bladder was drained through a Foley catheter placed 
in the urethra, and the balloon was inflated with 10 cc 
saline. The catheter had to be pushed far in the bladder and 
fixed to the glans with a sticky tape in order to avoid blow-
ing up the balloon during the procedure. The catheter was 
clamped with a spigot during the whole procedure in order 
to keep the bladder full which will improve the visualiza-
tion of the limits of the prostate by ultrasound.
The Anesthetist should avoid excess fluid supply as a 
full bladder could trigger movements and even waken the 
patient, as well as it could alter the shape of the prostate by 
compressing its base.
The patient was integrally protected from light exposure. 
The only exposed zone was the perineum.
Fig. 6  The ultrasound probe, the balloon and the brachystepper 
device
Fig. 7  Reusable transperineal prostate template
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Procedure
Once the installation was achieved, transparent hollow 
FICs were positioned into the prostate transperineally 
through the template (Figs. 7, 8), using the TRUS scan sys-
tem in accordance with the treatment guidance provided 
by the software TOOGUIDE®. The virtual template grid 
on the screen increased the accuracy of the FIC placement. 
Using FICs with metallic tips facilitated their penetration 
through the skin and the prostate. The best way to intro-
duce the FIC was to do it swiftly. A slow movement would 
make the skin more difficult to pass through and displace 
the prostate leading to a wrong position of the FIC into the 
targeted area. Conventionally, the FICs were inserted from 
anterior to posterior and from right to left. By using this 
method, the visualization of the posterior FICs during the 
introduction was not disturbed by the artifacts due to the 
FICs already in place. The right to left convention was very 
helpful to label each FIC and its corresponding optical fiber 
in a right and reproducible order.
Once all the FICs were in place, the accurate measure-
ment of each corresponding optical fiber was performed. 
The positions of the optical fibers into the FICs must 
respect a safety margin of 5 mm to the urethra, the rec-
tal wall, the sphincter and the capsula (Fig. 9). The dif-
fusing lengths of the optical fibers (10–50 mm) were cho-
sen according to the sagittal length of the prostate minus 
5-mm safety distance from the apex. According to each 
measurement, the corresponding diffusing optical fib-
ers were inserted into the FIC. Before the insertion, these 
optical fibers had to be calibrated by inserting their illu-
minating diffusor into the integrating sphere in the laser 
generator, in order to adjust the power with the planned 
values (within ±5 mW). O-ring clamps were used to lock 
the optical fibers in the catheters. Each fiber must be care-
fully pushed to the bottom of the FIC in order to have the 
illuminating diffusor perfectly positioned into the prostate. 
To avoid any displacement of the fibers in the prostate, the 
set of the optical fibers was carefully stuck to the trans-
parent drape with steri-strips. The positions of these fibers 
defined a precise targeted treatment area that resulted in 
a sharp controlled necrosis volume according to the treat-
ment guidance. With the optimal treatment conditions: 
each centimeter of fiber induced 0.8–1 cm3 of necrosis 
with more than 90 % of necrosis of the targeted volume 
[1]. At the end of this stage of the procedure, the surgeon 
had to verify that the Light Density Index (LDI) was above 
one fulfilling an additional optimal condition further to 
the hemi ablation approach [2]. Before the infusion of the 
photosensitizer, a safety light test is performed putting a 
light detection probe in the lumen of the rectum anteriorly 
to the endocavity balloon. After illuminating all the opti-
cal fibers placed into the prostate (“test mode” in the laser 
generator screen), the rectal light probe was moved in and 
out until reaching the highest level of light intensity with 
a maximum allowed of 13 mW/cm2. Above this threshold, 
the first measure taken was to deflate the balloon in order 
to increase the distance between the posterior part of the 
Fig. 8  Fiber insertion catheter
Fig. 9  Safety margin for the optical fiber positions
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prostate and the anterior rectal wall. If it was insufficient, 
the endorectal probe was moved posteriorly by using the 
Z-axis of the brachystepper in order to obtain an accept-
able light intensity level into the anterior rectal wall. Once 
the adequate light level was obtained, the US probe should 
not be moved anymore in order to keep the light monitor 
in place.
Once all FICs and optical fibers were in position, the 
light of the room was dimmed and the patient was entirely 
protected from light exposure and wear goggles. The infu-
sion of TOOKAD® Soluble was then initiated through 
opaque syringe and line.
Patient received a 10-min single intravenous adminis-
tration of 4 mg/kg TOOKAD® Soluble. The activation of 
the TOOKAD® Soluble was achieved by continuous illu-
mination of the prostate gland through the optical fibers 
with a 753-nm laser light at a power of 150 mW/cm and 
light energy of 200 J/cm delivered by a multichannel diode 
laser (Fig. 10). The illumination started immediately after 
the end of the injection during 22 min and 15 s in order to 
coincide with the peak serum concentration of TOOKAD® 
Soluble [5, 6].
The total duration of the whole procedure lasted 
between 1.5 and 2 h (including anesthesia, fiber place-
ment and illumination) and depended on the volume of 
the targeted area and the number of optical fibers to be 
placed (Fig. 11). At the end of the illumination, the laser 
was turned off and the FICs and optical fibers were with-
drawn at once from the prostate. The indwelling catheter 
was connected to a urinary bag. It was mandatory keep-
ing the patient completely covered with a sheet during the 
removal of the sterile drape and during his transfer from 
the operating table to his bed. In order to ease the commu-
nication and to avoid any stress, a bed cradle kept the sheet 
at distance from the face of the patient until his face could 
be uncovered.
Postoperative management
The patient was kept under medical surveillance under 
dimmed light for at least 6 h and may be discharged on the 
day of the procedure as a day-case surgery. The patient was 
informed that he had to avoid direct exposure to sunlight 
during 48 h after the injection. Dimmed light was recom-
mended the day of the procedure. The urinary catheter 
could be removed 3–4 h after the procedure or on the fol-
lowing day. An alpha-blocker was prescribed because of 
the increased risk of LUTS during the first month after the 
procedure.
Conclusion
Vascular-targeted photodynamic therapy with TOOKAD® 
Soluble (WST11) is a standardized procedure for local-
ized prostate cancer treatment. It is relatively simple, easy 
to learn and easy to perform. It is minimally invasive and 
requires a short anesthesia (approximatively 2 h), therefor 
it can be done in ambulatory conditions. The evolution of 
the technical procedure has been the result hundreds of 
cases in various environments such as public or private sec-
tors, university or general hospitals. The shared experience 
on various continents with different medical cultures of the 
surgeons involved in the studies improved the technique in 
a way to adapt itself to a vast majority of surgical centers 
with an optimal safety and efficacy of the treatment.
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Fig. 10  Laser generator
Fig. 11  VTP preoperative view
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